- Home
- NUS vs TSHA Comparison
NUS vs TSHA Comparison
Compare NUS & TSHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NUS | TSHA |
|---|---|---|
| Founded | 1984 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Pharmaceuticals | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 603.4M | 1.2B |
| IPO Year | 1996 | 2020 |
Fundamental Metrics
Financial Performance| Metric | NUS | TSHA |
|---|---|---|
| Price | $9.96 | $4.77 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 9 |
| Target Price | $7.00 | ★ $10.22 |
| AVG Volume (30 Days) | 506.8K | ★ 3.9M |
| Earning Date | 11-06-2025 | 11-04-2025 |
| Dividend Yield | ★ 2.43% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 2.20 | N/A |
| Revenue | ★ $1,560,391,000.00 | $6,310,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $0.98 | N/A |
| P/E Ratio | $4.49 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $5.32 | $1.05 |
| 52 Week High | $14.62 | $5.51 |
Technical Indicators
Market Signals| Indicator | NUS | TSHA |
|---|---|---|
| Relative Strength Index (RSI) | 46.23 | 59.35 |
| Support Level | $9.32 | $3.92 |
| Resistance Level | $10.46 | $4.34 |
| Average True Range (ATR) | 0.42 | 0.29 |
| MACD | 0.09 | 0.07 |
| Stochastic Oscillator | 61.74 | 86.27 |
Price Performance
Historical ComparisonAbout NUS Nu Skin Enterprises Inc.
Nu Skin Enterprises Inc is a health and beauty direct-selling company. It has two primary product categories: beauty products and wellness products. The company develops and distributes nutritional, weight-management products, and food supplements under the Nu Skin and Pharmanex brands, respectively. The company has operations internationally, in more than 50 countries across the Americas, Europe, and the Asia-Pacific.
About TSHA Taysha Gene Therapies Inc.
Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. Its product pipeline includes, TSHA-102 which is a is a self-complementary intrathecally delivered AAV9 gene transfer therapy in clinical evaluation for Rett syndrome.